We are live on ! Find out more
CURX

Curanex Pharmaceuticals

11 hedge funds and large institutions have $89K invested in Curanex Pharmaceuticals in 2026 Q2 according to their latest regulatory filings, with 6 funds opening new positions, 2 increasing their positions, 3 reducing their positions, and 3 closing their positions.

New
Increased
Maintained
Reduced
Closed

100% more first-time investments, than exits

New positions opened: 6 | Existing positions closed: 3

38% more funds holding

Funds holding: 811 (+3)

0.02% more ownership

Funds ownership: 1.16%1.18% (+0.02%)

33% less repeat investments, than reductions

Existing positions increased: 2 | Existing positions reduced: 3

47% less capital invested

Capital invested by funds: $168K → $89K (-$78.6K)

Holders
11
Holders Change
+3
Holders Change %
+37.5%
% of All Funds
0.13%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
6
Increased
2
Reduced
3
Closed
3
Calls
Puts
Net Calls
Net Calls Change

CURX Hedge Fund Activity: Q2 2026 in Review

11 of the 8,336 institutional investors tracked by Wall St. Rank reported a position in Curanex Pharmaceuticals (CURX) for Q2 2026, worth a combined $89K — down 47% from $168K a quarter earlier.

Buyers outnumbered sellers: 6 funds opened new CURX positions and 3 closed out — a net gain of 3 holders — while 2 added to existing stakes and 3 trimmed.

The largest buyer was Renaissance Technologies, opening a new position worth an estimated $18.9K. The largest seller was Two Sigma Securities, exiting entirely with an estimated $29K sold.

  • 11 institutional investors held Curanex Pharmaceuticals (CURX) as of Q2 2026, up from 8 in Q1 2026.
  • Funds reported $89K of Curanex Pharmaceuticals stock for Q2 2026, down 47% quarter-over-quarter.
  • 6 funds opened new Curanex Pharmaceuticals positions in Q2 2026 and 3 closed out, a net change of +3 holders.
  • The largest Curanex Pharmaceuticals buyer in Q2 2026 was Renaissance Technologies, an estimated $18.9K added.
  • The largest Curanex Pharmaceuticals seller in Q2 2026 was Two Sigma Securities, an estimated $29K sold.

Based on aggregated 13F filings for Q2 2026.